Servier in licensing pact with SIMM for the development in China of lucitanib

Servier has signed an agreement with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, (SIMM)  for the development in China of lucitanib, a promising targeted anti-tumor drug with antiangiogenic effects. The drug has demonstrated impressive efficacy in PhI/PhII trials in metastatic breast cancer patients. 

Amgen inlicenses US rights for CHF drug from Servier

AMGN announced a deal with Servier (a privately held French pharma) to gain US rights to  Procoralan. Procoralan is an oral drug indicated for treatment of chronic heart failure and stable angina (chest pain). Amgen will pay $50mn upfront payment and future undisclosed milestones and royalties.